Practice
Medical cannabinoids
Scott A. McLeod and Jean-François Lemay
CMAJ July 31, 2017 189 (30) E995; DOI: https://doi.org/10.1503/cmaj.161395
Scott A. McLeod
Department of Pediatrics (McLeod, Lemay), Cumming School of Medicine, University of Calgary, Alberta Children’s Hospital, Calgary, Alta.
MDJean-François Lemay
Department of Pediatrics (McLeod, Lemay), Cumming School of Medicine, University of Calgary, Alberta Children’s Hospital, Calgary, Alta.
MDRelated Articles
- (2017). Medical cannabinoids. CMAJ, 189(34), E1099. Accessed April 18, 2024. https://doi.org/10.1503/cmaj.170904.
In this issue
Article tools
Respond to this article
Medical cannabinoids
Scott A. McLeod, Jean-François Lemay
CMAJ Jul 2017, 189 (30) E995; DOI: 10.1503/cmaj.161395
Jump to section
- Article
- The principal cannabinoids, cannabidiol and tetrahydrocannabinol, have different medical effects
- Despite widespread availability, medical cannabinoids are still experimental
- Cannabinoids can increase the risk of motor vehicle collisions4
- Cannabinoids should be titrated slowly with low initial dosing
- Users of medical cannabinoids may be vulnerable to psychosis
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis
- Simplified guideline for prescribing medical cannabinoids in primary care
- Lignes directrices simplifiees en matiere de prescription de cannabinoides medicaux en soins de premiere ligne
- Medical cannabinoids